RxDoctor Payments Data

Masumi Ueda Oshima, MD

Hematology & Oncology · Seattle, WANPI 1235454786

Payments from drug & device makers

What this record shows

That places this record below the midpoint for hematology & oncology clinicians in WA, where the typical reported total is $899.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$1,987,722in research payments, 2019–2025

Across 163 payments — averaging $12,195 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$1.6M
  • National Marrow Donor Program$259K
  • Astellas Pharma Global Development$84K
  • Vectivbio AG$6K

How this compares

$0 in reported general payments places this provider in the 0th percentile of 349 hematology & oncology providers in Washington.

See all hematology & oncology providers in Washington

Medicare billing

Part B allowed, 2024
$23,069
Medicare patients
54
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →